Application of Next-Generation Sequencing (NGS) to improve cancer management: A review of the clinical effectiveness and cost-effectiveness.

We report the rate of successfully detecting mutations from the clinical studies. The Incremental Cost-Effectiveness Ratio and sensitivity analysis outcomes are reported for the cost-effectiveness articles. Fifty-six articles reported that sequencing patient samples using targeted gene panels, and 83% of the successfully sequenced patients harboured at least one mutation. Only six studies reported on the cost-effectiveness of the application of NGS in cancer care. NGS is an effective tool for identifying mutation in cancer patients. However, more rigorous cost-effectiveness studies of NGS applied to cancer management are needed to determine whether NGS can improve patient outcomes cost-effectively. PMID: 29265354 [PubMed - as supplied by publisher]
Source: Clinical Genetics - Category: Genetics & Stem Cells Authors: Tags: Clin Genet Source Type: research